Drug
Enzalutamide clinical trials
Also written Xtandi, MDV3100 and ASP9785.
- studies test it
- 198
- open now
- 30
- in phase 3
- 25
- first study started
- 2005
Keep track of what changes. Save the enzalutamide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Enzalutamide
- 171
Brand
- Xtandi
- 127
Studies by the year they started
198 studies that test it; most in 2014 (27)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 8 |
| 2012 | 6 |
| 2013 | 14 |
| 2014 | 27 |
| 2015 | 22 |
| 2016 | 15 |
| 2017 | 18 |
| 2018 | 7 |
| 2019 | 19 |
| 2020 | 13 |
| 2021 | 9 |
| 2022 | 7 |
| 2023 | 6 |
| 2024 | 11 |
| 2025 | 5 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 66
- Phase 2
- 120
- Phase 3
- 25
- Phase 4
- 9
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 81 · Other 117
Pfizer (16) · Astellas Pharma Europe B.V. (11) · Astellas Pharma Global Development, Inc. (10) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (7) · Astellas Pharma Inc (7) · M.D. Anderson Cancer Center (6) · Memorial Sloan Kettering Cancer Center (5) · OHSU Knight Cancer Institute (4)
Often tested with
Tested in the same studies.
Abiraterone (27) · Abiraterone Acetate (14) · Docetaxel (8) · Paclitaxel (7) · Cabazitaxel (6) · Pembrolizumab (6) · Prednisone (6) · Darolutamide (6)
Studies
Open first, then newest update. How each study uses enzalutamide is read from its arms, and is right about nine times in ten.
Testing it · 198
- Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1/2Evopoint Biosciences Inc.NCT06702995Written as enzalutamide
- Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT05873192Written as Enzalutamide
- A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07783282Written as enzalutamide
- A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCRecruitingPhase 1/2Novartis PharmaceuticalsNCT07226986Written as Enzalutamide
- Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate CancerRecruitingPhase 2Fundacion OncosurNCT06582628Written as Enzalutamide capsule
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT06632977Written as Enzalutamide
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Enzalutamide
- Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial OriginRecruitingPhase 1M.D. Anderson Cancer CenterNCT06576037Written as Enzalutamide
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationPhase 3ExelixisNCT07620574Written as Enzalutamide
- Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT06236139Written as Enzalutamide
- Enzalutamide Implants (Enolen) in Patients With Prostate CancerRecruitingPhase 1Alessa Therapeutics Inc.NCT06257693Written as enzalutamide
- Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.RecruitingPhase 2Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología RadioterápicNCT07717268Written as Xtandi
- Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate CancerNot yet recruitingPhase 1Hyundai Bioscience Co., Ltd.NCT07683013Written as Enzalutamide 40 mg capsule
- The COSMYC Trial (COmbined Suppression of MYC)RecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06922318Written as Enzalutamide
- Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL TrialRecruitingPhase 2Sean SachdevNCT06499870Written as Enzalutamide
- Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate CancerRecruitingPhase 2Syntrix Biosystems, Inc.NCT06228053Written as Enzalutamide
- A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor TherapyNot yet recruitingPhase 2Prostate Cancer Clinical Trials ConsortiumNCT07592910Written as Enzalutamide
- Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1/2University of Michigan Rogel Cancer CenterNCT06616155Written as Enzalutamide
- Relugolix + Enzalutamide Study in High-Risk Prostate CancerRecruitingPhase 1University of OklahomaNCT06130995Written as Relugolix and Enzalutamide
- A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06099769Written as Enzalutamide
See all 198 studies that test enzalutamide →
Given in every arm · 83 — enzalutamide is usual care beside what is tested
- A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate CancerRecruitingPhase 1Novartis PharmaceuticalsNCT07570979Written as Enzalutamide
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsRecruitingPhase 1/2DualityBio Inc.NCT05914116Written as Enzalutamide
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingPhase 1/2PfizerNCT04557449Written as Enzalutamide
- Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT06096870Written as Enzalutamide
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaRecruitingPhase 1PfizerNCT03460977Written as Enzalutamide
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)RecruitingPhase 3AstraZenecaNCT07711002Written as Enzalutamide
- A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.RecruitingPhase 3PfizerNCT06629779Written as Enzalutamide
- This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.RecruitingPhase 3PfizerNCT07028853Written as Enzalutamide
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06863272Written as Enzalutamide
- A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Hoffmann-La RocheNCT07287150Written as Enzalutamide
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT05818683Written as Enzalutamide
- A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid TumorsRecruitingPhase 1GlaxoSmithKlineNCT07277270Written as Enzalutamide
- A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate CancerRecruitingPhase 2University of ChicagoNCT05726292Written as Enzalutamide
- Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)Not yet recruitingPhase 3Ente Ospedaliero Cantonale, BellinzonaNCT07782112Written as Enzalutamide
- Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1AmgenNCT04221542Written as Enzalutamide
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingPhase 1/2Novartis PharmaceuticalsNCT04104776Written as Enzalutamide
- The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)RecruitingPhase 3Telix Pharmaceuticals (Innovations) Pty LimitedNCT06520345Written as Enzalutamide
- Sequential Testosterone and Enzalutamide Prevents Unfavorable ProgressionRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04363164Written as Enzalutamide
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseRecruitingPhase 3Canadian Cancer Trials GroupNCT06592924Written as Enzalutamide
- Study of ORIC-944 in Patients With Metastatic Prostate CancerRecruitingPhase 1ORIC PharmaceuticalsNCT05413421Written as Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
Showing 20 of 83.
As the comparator · 25 — what is tested is compared with enzalutamide
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136650Written as Enzalutamide
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)RecruitingPhase 3AstraZenecaNCT07611110Written as Enzalutamide
- Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)RecruitingPhase 2TransThera Sciences (Nanjing), Inc.NCT07871110Written as Enzalutamide 160mg daily (oral)
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136624Written as Enzalutamide
- A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)RecruitingPhase 3ORIC PharmaceuticalsNCT07723248Written as Enzalutamide
- A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]RecruitingPhase 3GlaxoSmithKlineNCT07802704Written as Enzalutamide
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNot yet recruitingPhase 2/3ECOG-ACRIN Cancer Research GroupNCT07852195Written as Enzalutamide
- A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or DarolutamideRecruitingPhase 2Prostate Cancer Clinical Trials ConsortiumNCT06844383Written as Talazoparib with enzalutamide
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecruitingPhase 2Mayo ClinicNCT06378866Written as Enzalutamide
- Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.RecruitingPhase 2Sun Pharmaceutical Industries LimitedNCT05422911Written as Enzalutamide
- An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Active, not recruitingPhase 2Novartis PharmaceuticalsNCT06991556Written as Enzalutamide
- A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 3CelgeneNCT06764485Written as Enzalutamide
- A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate CancerCompletedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT03314324Written as Enzalutamide
- Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)Active, not recruitingPhase 3AmgenNCT06691984Written as Enzalutamide
- Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsActive, not recruitingPhase 4AstraZenecaNCT05457257Written as enzalutamide
- A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With EnzalutamideCompletedPhase 2BayerNCT05526248Written as Enzalutamide
- A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsTerminatedPhase 2MacroGenicsNCT05551117Written as Enzalutamide
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentActive, not recruitingPhase 3POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyNCT04647526Written as Enzalutamide
- Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCActive, not recruitingPhase 3ExelixisNCT04446117Written as Enzalutamide
- Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)CompletedPhase 3Merck Sharp & Dohme LLCNCT03834519Written as Enzalutamide
Showing 20 of 25.
Codes
What other systems call enzalutamide · ClinicalTrials.gg INT005424
- MeSH (NLM) C540278enzalutamideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 93T0T9GKNUENZALUTAMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1307298Confirmed FDA, Wikidata
- Wikidata Q1996756enzalutamideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71744EnzalutamideOne source FDA
- DrugBank DB08899One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C540278 | enzalutamide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 93T0T9GKNU | ENZALUTAMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1307298 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1996756 | enzalutamide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71744 | Enzalutamide | One source FDA |
| DrugBank | DB08899 | — | One source Wikidata |
Also registered as deutenzalutamide (UNII 3OKI556HC2).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.